76 related articles for article (PubMed ID: 21597801)
1. Cross-resistance to antineoplastic agents in a human small-cell lung-cancer subline resistant to okadaic Acid.
Takeda Y; Kubota N; Nishio K; Funayama Y; Gemma A; Niitani H; Saijo N
Oncol Rep; 1995 Sep; 2(5):705-10. PubMed ID: 21597801
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a human small-cell lung-cancer subline resistant to okadaic acid.
Takeda Y; Nishio K; Kubota N; Miura K; Morikage T; Ohmori T; Kudoh S; Niitani H; Saijo N
Int J Cancer; 1994 Sep; 58(6):882-90. PubMed ID: 7927883
[TBL] [Abstract][Full Text] [Related]
3. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
4. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
7. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells.
Brock I; Hipfner DR; Nielsen BS; Jensen PB; Deeley RG; Cole SP; Sehested M
Cancer Res; 1995 Feb; 55(3):459-62. PubMed ID: 7834606
[TBL] [Abstract][Full Text] [Related]
8. Cellular models of drug- and radiation-resistant small cell lung cancer.
Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a taxol-resistant human small-cell lung cancer cell line.
Ohta S; Nishio K; Kubota N; Ohmori T; Funayama Y; Ohira T; Nakajima H; Adachi M; Saijo N
Jpn J Cancer Res; 1994 Mar; 85(3):290-7. PubMed ID: 7514586
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
Nishio K; Sugimoto Y; Nakagawa K; Niimi S; Fujiwara Y; Bungo M; Kasahara K; Fujiki H; Saijo N
Br J Cancer; 1990 Sep; 62(3):415-9. PubMed ID: 2206949
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
12. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Mirski SE; Gerlach JH; Cole SP
Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
[TBL] [Abstract][Full Text] [Related]
14. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
15. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
[TBL] [Abstract][Full Text] [Related]
16. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
Cole SP; Downes HF; Mirski SE; Clements DJ
Mol Pharmacol; 1990 Feb; 37(2):192-7. PubMed ID: 1968221
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
Ohta S; Nishio K; Kubo S; Nishio M; Ohmori T; Takahashi T; Saijo N
Br J Cancer; 1993 Jul; 68(1):74-9. PubMed ID: 8391305
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
19. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells.
Gollapudi S; Kim CH; Tran BN; Sangha S; Gupta S
Cancer Chemother Pharmacol; 1997; 40(2):150-8. PubMed ID: 9182837
[TBL] [Abstract][Full Text] [Related]
20. Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69.
Reeve JG; Rabbitts PH; Twentyman PR
Br J Cancer; 1989 Sep; 60(3):339-42. PubMed ID: 2571355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
